Incyte

(NASDAQ: INCY)
Health Care  |  Biotechnology
90.56 -1.48 -1.61%
Stock Price | Jan. 15, 2021, 4 p.m.
0 Followers
Bid:
Ask:
Prev. Close: 92.04
52 Week Low: 62.48
52 Week High: 110.365
PE Ratio:
Dividend Yield: %

Company Summary

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more Read less

Recently Viewed Tickers